Long-term Nerve Regeneration in Diabetic Keratopathy Mediated by a Novel NGF Delivery System


Here are the Long-term Nerve Regeneration in Diabetic Keratopathy Mediated by a Novel NGF Delivery System journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Long term capital gains tax 2025, long term nerve pain after surgery, long term nerve regeneration in diabetic keratopathy treatment, long term nerve regeneration in the pns, long term nerve regeneration in diabetic ketoacidosis, long term nerve regeneration in foot.

Long-term Nerve Regeneration in Diabetic Keratopathy Mediated by a Novel NGF Delivery System

Diabetic keratopathy (DK) is a common chronic metabolic disorder that causes ocular surface complications. Among various therapeutic approaches, local delivery of nerve growth factor (NGF) remains the most effective treatment of DK. However, achieving a sustained therapeutic effect with NGF and the frequent drug delivery burden remain challenging during clinical practice. Here, we developed a novel adeno-associated virus (AAV)-based NGF delivery system that achieved 1-year-long-lasting effects by a single injection. We refined the corneal stromal injection technique, resulting in reduced corneal edema and improved AAV distribution homogeneity. AAV serotype AAV.rh10 exhibited high tropism and specificity to corneal nerves. A dose of 2 × 109 vector genomes was determined to achieve efficient Ngf gene expression without inducing corneal immune responses. Moreover, NGF protein was highly expressed in trigeminal ganglion through a retrograde transport mechanism, indicating the ca pacity for repairing corneal nerve damage at both the root and corneal nerve endings. In a mouse DK model, a single injection of AAV-Ngf into the corneal stroma led to marked corneal nerve regeneration for over 5 months. Together, we provide a novel therapeutic paradigm for long-term effective treatment of DK, and this therapeutic approach is superior to current DK therapies. © 2024 by the American Diabetes Association.

Authors : Cong L.; Qi B.; Chen S.; Liu R.; Li S.; Zhou Q.; Cao Y.; Zhang B.N.; Xie L.

Source : American Diabetes Association Inc.

Article Information

Year 2025
Type Article
DOI 10.2337/db24-0393
ISSN 00121797
Volume 74

You can download the article here


If You have any problem, contact us here


Support Us:

Download Now Buy me a coffee Request Paper Here